Following Its Recent Approval in the United States and Europe for Osteoporosis, Prolia Will Garner Sales of More than $500 Milli

Prolia's Uptake Will Be Constrained by Its Premium Price and the Increasing Availability of Generic Drugs, According to Findings from Decision Resources

WALTHAM, Mass., July 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of Amgen/GlaxoSmithKline's Prolia will drive this agent to garner sales of more than $500 million in 2019 for postmenopausal osteoporosis in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additional sales of Prolia will come from a number of oncology-related indications, which await regulatory approval.

The Pharmacor 2010 findings from the topic entitled Osteoporosis reveal that uptake of Prolia will be driven by its twice yearly, subcutaneous delivery, which interviewed experts believe will foster better patient compliance than other agents in the market such as generic alendronate and sanofi-aventis/Warner Chilcott's Actonel. Interviewed experts regard Prolia's subcutaneous delivery as more convenient than that of alendronate and Actonel. However, Prolia's uptake in the mature osteoporosis drug market will be constrained by the increasing availability of generic versions of established agents, safety concerns, and its premium price when compared to existing treatments.

"A number of safety issues related to long-term use of bisphosphonates concern both physicians and patients," said Decision Resources Analyst Matthew Scutcher, Ph.D. "Experts we interviewed believe that Prolia is likely to cause many of the same adverse effects as those of the bisphosphonates, thereby negating any safety advantage that would have propelled Prolia to blockbuster status."

The Pharmacor 2010 findings also reveal that the recent withdrawal for marketing authorization (MA) in Europe of Pfizer's selective estrogen receptor modulator (SERM) bazedoxifene is a significant setback for the agent's development in osteoporosis. The withdrawal of bazedoxifene's MA application also casts doubt about the future of new members of the SERM drug class that are in development for osteoporosis and osteopenia.

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:


Decision Resources, Inc.

Christopher Comfort

781-296-2597

[email protected]



SOURCE Decision Resources

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.